Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01736371
Other study ID # Cis-sevo-123
Secondary ID
Status Completed
Phase N/A
First received November 25, 2012
Last updated November 28, 2012
Start date January 2012
Est. completion date November 2012

Study information

Verified date November 2012
Source Tianjin Medical University General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim in this study was to quantify the difference in cisatracurium and sufentanil consumption, and its recovery period, when patients are under balanced general anesthesia with 1% sevoflurane and patients under only sevoflurane general anesthesia, using a closed loop computer control infusion. Investigators further investigated this effect on its recovery period and sufentanyl consumption.


Description:

156 patients of American Society of Anesthesiologists (ASA) physical status I and II were assigned to three groups. The patients were all on schedule for elective general surgery under general anesthesia with duration of at two to four hours. All patients were induced with Etomidate (0.2mg/kg), Midazolam (0.05-0.1mg/kg), Sufentanil (0.3-0.5µg/kg) and a bolus dose of Cisatracurium (0.15mg/kg). Patients were aged between 20 and 65. The maintenance of anesthesia in each group varies as follows: Patients in Group 1 were all maintained with Total Intravenous Anesthesia, Group 2 with Sevoflurane at 1% and propofol infusion, Group 3 with only sevoflurane. Muscle paralysis is maintained using a closed-loop computer gated infusion of Cisatracurium which kept T1 <1% by giving increasing the infusion rate intra-operatively when required. Analgesia was maintained by intermittent bolus dose of 10-20 µg of Sufentanil.


Recruitment information / eligibility

Status Completed
Enrollment 156
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients aged 20 and 65.

- Patients with ASA 1 and 2.

- Patients for elective abdominal general surgery

Exclusion Criteria:

- Patients with the following diseases are excluded, since they are known to cause generalized neuromuscular weakness:

Neuromuscular junction disorders (e.g.. myasthenia gravis) Myopathies (e.g.. Muscular Dystrophies, Rhabdomyolysis) Peripheral Neuropathies (e.g. Guillain-Barre Syndrome, Polyneuropathies) Encephalopathies (Septic and Toxic-metabolic Encephalopathy) Patients with renal and liver diseases.

- Patients who are sent intubated to ICU after surgery.

- Patients refusal

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
1% Sevoflurane
In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
Propofol
In this group the maintenance of anesthesia is maintained by only propofol infusion.
Sevoflurane
In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.

Locations

Country Name City State
China Tianjin Medical University Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Sufentanil Consumption. Measurements were done intraoperatively, from which the intra-operative consumption of sufentanil were obtained from each patient. Data were collected only during surgery. Investigators compared the average sufentanil consumption between between groups. At time of surgery
Primary Cisatracurium consumption rate. Measurements were done intraoperatively. Investigators obtained data from the closed loop computer system, from which the intra-operative consumption of cisatracurium were obtained from each patient. Data were collected only during surgery. Each patient had different cisatracurium consumption rate, and the mean consumption rate of the patients within the same group were calculated, and compared with the means from the other groups. At the time of surgery.
Secondary Analysis of Means of Recovery Index. Recovery Index was the time for the Train-Of-Four ratio (TOF) to increase from 25% to 75%. The TOF ratio was recorded every minute till it reached 90%. Time taken for each patient was from 5 to 25 minutes. Investigators compared the average recovery index of patients from each group. 30 minutes post operative.
See also
  Status Clinical Trial Phase
Completed NCT03789032 - Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Phase 1
Completed NCT03706222 - Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
Completed NCT02191358 - YouScript IMPACT Registry N/A
Completed NCT02485028 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg Phase 1
Completed NCT01896557 - Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Phase 4
Completed NCT03011463 - Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 Phase 1
Completed NCT02485041 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg Phase 1
Completed NCT01477424 - A Drug-Drug Interaction Study of Warfarin and PA21 Phase 1
Completed NCT01477411 - A Drug-Drug Interaction Study of Digoxin and PA21 Phase 1
Completed NCT05558150 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac Phase 1
Completed NCT03493698 - A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects Phase 1
Completed NCT03126578 - Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam Phase 1
Completed NCT01369186 - Drug Drug Interactions of Aspirin and P2Y12-inhibitors Phase 4
Completed NCT02378220 - Pharmacogenetic Testing Among Home Health Patients N/A
Completed NCT01324752 - A Drug-Drug Interaction Study of Losartan and PA21 Phase 1
Completed NCT02500667 - A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects Phase 1
Completed NCT03801733 - Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin Phase 1
Completed NCT03801746 - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin Phase 1
Completed NCT03801759 - Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Phase 1
Completed NCT05237297 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole Phase 1